Provided by Tiger Trade Technology Pte. Ltd.

Moderna, Inc.

154.27
+13.939.93%
Post-market: 153.51-0.7600-0.49%16:06 EDT
Volume:25.26M
Turnover:3.75B
Market Cap:61.59B
PE:-19.27
High:154.70
Open:140.25
Low:138.09
Close:140.34
52wk High:176.66
52wk Low:22.28
Shares:399.24M
Float Shares:368.05M
Volume Ratio:0.90
T/O Rate:6.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.0076
EPS(LYR):-7.2600
ROE:-39.00%
ROA:-13.26%
PB:9.11
PE(LYR):-21.25

Loading ...

Moderna (MRNA) Receives a Hold from Bernstein

TIPRANKS
·
Jul 23

Cboe data shows mixed options sentiment in Moderna with shares down 1.48%

TIPRANKS
·
Jul 23

Biotech Experts Want FDA Drug Reviews Based on Science, not Politics

Reuters
·
Jul 22

What Bundibugyo Ebola Vaccines and Treatments are Under Development

Reuters
·
Jul 22

Moderna Inc. Stock Slides 3.8%, Underperforms Peers

Dow Jones
·
Jul 21

Moderna Says Curevac Broke Agreement by Suing over COVID Vaccine Patents

Reuters
·
Jul 21

Goldman Sachs Adjusts Moderna Price Target to $67 From $49, Maintains Neutral Rating

MT Newswires Live
·
Jul 20

Moderna President Stephen Hoge Disposes of Common Shares Worth $3.61 Million

Reuters
·
Jul 17

Moderna Inc. Stock Sheds 7.5%, Underperforms Peers

Dow Jones
·
Jul 17

Movement Alert|Moderna Falls 5.52% in Regular Trading, Patent Settlement Payment Pressure Sparks Market Concern

Market Focus
·
Jul 16

Stock Track | Moderna Plummets 5.08% Intraday Following $178 Million Patent Settlement Payment

Stock Track
·
Jul 16

Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents

MT Newswires Live
·
Jul 16

Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-targeted Cancer Antigen Therapy in Solid Tumors

THOMSON REUTERS
·
Jul 16

Arbutus Biopharma Corp - Expects to Return up to $230 Mln in Capital to Shareholders

THOMSON REUTERS
·
Jul 16

Moderna Doses First Patient in Phase 1 Trial of Mrna-4200 Cancer Therapy in Solid Tumors

Reuters
·
Jul 16

Sanofi Sues Pfizer, Moderna over COVID Shot Technology

Reuters
·
Jul 15

Decoy Therapeutics Adds Moderna Executive Patricia Gauthier to Board

Reuters
·
Jul 15

Jefferies Adjusts Price Target on Moderna to $60 From $53, Maintains Hold Rating

MT Newswires Live
·
Jul 13

US Stock Market Today: S&P 500 Futures Climb On Cooler Global Inflation And Yields

Simply Wall St.
·
Jul 13

Moderna : Jefferies Raises Target Price to $60 from $53

THOMSON REUTERS
·
Jul 13